Cite

HARVARD Citation

    Kojima, T. et al. (2018). Phase I dose‐escalation trial of Sym004, an anti‐EGFR antibody mixture, in Japanese patients with advanced solid tumors. Cancer science. 109 (10), pp. 3253-3262. [Online]. 
  
Back to record